Reported Awareness and Use of Pyridoxal-5'-Phosphate Supplementation in Alanine Aminotransferase and Aspartate Aminotransferase Assay Reagents: A Survey by the College of American Pathologists Clinical Chemistry Committee.

Autor:	Chambliss AB; From the Department of Pathology and Laboratory Medicine, University of California, Los Angeles (Chambliss)., Souers RJ; The Department of Biostatistics, College of American Pathologists, Northfield, Illinois (Souers)., Genzen JR; The Department of Pathology, University of Utah Health, Salt Lake City (Genzen).; ARUP Laboratories, Salt Lake City, Utah (Genzen)., Manthei DM; The Department of Pathology, University of Michigan, Ann Arbor (Manthei).
Jazyk:	angličtina
Zdroj:	Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Jul 25. Date of Electronic Publication: 2024 Jul 25.
DOI:	10.5858/arpa.2024-0097-CP
Abstrakt:	Context.—: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) assay reagents are available both with and without supplementation with pyridoxal-5'-phosphate (P5P; the active form of vitamin B6), a catalytic cofactor required for their enzymatic reactions. Nonsupplemented assays may miss ALT or AST elevations in patients with vitamin B6 deficiency. Objective.—: To assess awareness and adoption of ALT and AST reagents that are supplemented with P5P. Design.—: A 4-question survey about ALT and AST reagent supplementation with P5P was included in the College of American Pathologists General Chemistry and Therapeutic Drugs (C program) proficiency testing 2023 B mailing. Results.—: Overall, 38% (1651 of 4304) of responding laboratories reported using ALT and/or AST reagent supplemented with P5P. P5P supplementation was more common for nonacademic hospital/medical center laboratories (44%; 713 of 1629) relative to other settings. Of the laboratories that reported not using P5P-supplemented reagents, few (5%; 141 of 2611) cited plans to convert in the future. Despite the availability of P5P-supplemented reagents from several major assay manufacturers, the most common stated barrier for adoption was that the laboratory's reagent manufacturer does not provide P5P-supplemented reagents. Conclusions.—: There is a lack of awareness of the existence and benefits of P5P-supplemented ALT and AST reagents. There is a need for ALT and AST assay manufacturers to clarify and standardize the P5P status of ALT and AST reagents. Competing Interests: The authors have no relevant financial interest in the products or companies described in this article. (© 2024 College of American Pathologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu